{"original": "In relation to COVID-19, Friman et al. investigated the off-target effects of the broad-spectrum antiviral Remdesivir, one of the first drugs to be repurposed for use during the pandemic. Remdesivir was evaluated using thermal proteome profiling in a HepG2 cellular thermal shift assay, alongside the drug hydroxychloroquine, which has been subject to controversy. The study identified TRIP13 as a potential off-target for Remdesivir.\n\n\nIt ", "sampled": "about relation to COVID-19, group alii al. inspected the off-target effects in the broad-spectrum antiviral remedy, one of the first drugs to be redirected for use during the pandemic. Remdesivir was evaluated using thermal proteome profiling in a HepG2 cellular thermal shift assay, alongside the drug hydroxychloroquine, which has been subject to controversy. an study identified Receptor as a potential off-target for Remdesivir. It", "replacement_keys": [0, 4, 56, 53, 7, 5, 15, 11, 23], "original_crit": -1.2507908344268799, "sampled_crit": -2.203035354614258, "original_llm_likelihood": 0.49, "sampled_llm_likelihood": 0.21}